PG
$29.12
+0.68
(+2.39%)
As of Oct 22, 2026, 9:30 PM EDT · cached
Price history
Progyny Inc (PGNY) is trading up at $29.12 (+2.39%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: October 25, 2019 · $13.00 offering · NASDAQ · View IPO details →
Progyny Inc revenue & net income history (FY2017–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $48.6M | $105.4M | $229.7M | $344.9M | $500.6M | $786.9M | $1.09B | $1.17B | $1.29B |
| Growth (year over year) | — | +116.9% | +117.9% | +50.1% | +45.2% | +57.2% | +38.3% | +7.2% | +10.4% |
| Gross profit | $7.40M | $19.4M | $45.5M | $70.1M | $112.1M | $167.3M | $238.8M | $253.4M | $304.5M |
| Gross margin | 15.2% | 18.4% | 19.8% | 20.3% | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% |
| Operating income | −$11.0M | −$3.45M | $9.68M | $8.35M | $32.3M | $23.3M | $62.2M | $67.5M | $85.3M |
| Operating margin | −22.7% | −3.3% | 4.2% | 2.4% | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% |
| Net income | −$12.5M | $661.0K | −$8.57M | $46.5M | $65.8M | $30.4M | $62.0M | $54.3M | $58.5M |
| Net margin | −25.6% | 0.6% | −3.7% | 13.5% | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% |
| EPS (diluted) | −$2.37 | $0.04 | −$0.41 | $0.47 | $0.66 | $0.30 | $0.62 | $0.57 | $0.65 |
| Balance sheet | |||||||||
| Cash and equivalents | — | $127.0K | $80.4M | $70.3M | $91.4M | $120.1M | $97.3M | $162.3M | $112.2M |
| Total assets | — | $41.3M | $150.4M | $253.9M | $358.1M | $543.0M | $756.6M | $607.1M | $742.4M |
| Total liabilities | — | $30.2M | $36.2M | $87.0M | $106.2M | $166.0M | $203.2M | $185.0M | $226.4M |
| Shareholders' equity | −$97.6M | −$95.1M | $114.3M | $166.9M | $251.8M | $377.0M | $553.4M | $422.1M | $516.0M |
| Cash flow | |||||||||
| Operating cash flow | −$9.47M | $2.27M | −$1.53M | $36.2M | $26.0M | $80.4M | $188.8M | $179.1M | $210.2M |
| Capital expenditure | $612.0K | $579.0K | $2.96M | $1.04M | $2.13M | $3.24M | $3.64M | $5.41M | $18.4M |
| Free cash flow | −$10.1M | $1.69M | −$4.49M | $35.2M | $23.9M | $77.2M | $185.2M | $173.7M | $191.8M |
| Share buybacks | — | $1.21M | $185.0K | — | — | $0 | $0 | $300.3M | $81.7M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $286.6M | $298.4M | $324.0M | $332.9M | $313.3M | $318.4M | $328.5M | $350.5M |
| Growth (year over year) | +2.0% | +10.6% | +16.5% | +9.5% | +9.3% | +6.7% | +1.4% | +5.3% |
| Gross profit | $59.2M | $63.4M | $75.8M | $79.0M | $72.8M | $76.9M | $83.1M | $89.3M |
| Gross margin | 20.7% | 21.3% | 23.4% | 23.7% | 23.2% | 24.1% | 25.3% | 25.5% |
| Operating income | $12.5M | $15.8M | $24.2M | $24.4M | $21.5M | $15.2M | $35.4M | $40.0M |
| Operating margin | 4.3% | 5.3% | 7.5% | 7.3% | 6.9% | 4.8% | 10.8% | 11.4% |
| Net income | $10.4M | $10.5M | $15.1M | $17.1M | $13.9M | $12.5M | $24.2M | $28.1M |
| Net margin | 3.6% | 3.5% | 4.6% | 5.1% | 4.4% | 3.9% | 7.4% | 8.0% |
| EPS (diluted) | $0.11 | $0.12 | $0.17 | $0.19 | $0.15 | $0.14 | $0.29 | $0.34 |
| Balance sheet | ||||||||
| Cash and equivalents | $91.5M | $162.3M | $109.2M | $132.5M | $134.0M | $112.2M | $131.6M | $152.6M |
| Total assets | $660.0M | $607.1M | $730.3M | $761.0M | $795.2M | $742.4M | $698.3M | $715.8M |
| Total liabilities | $225.1M | $185.0M | $263.1M | $245.9M | $235.2M | $226.4M | $259.0M | $262.6M |
| Shareholders' equity | $434.9M | $422.1M | $467.2M | $515.0M | $560.0M | $516.0M | $439.3M | $453.3M |
| Cash flow | ||||||||
| Operating cash flow | $44.5M | $52.2M | $49.8M | $55.5M | $50.7M | $54.2M | $45.9M | $50.4M |
| Capital expenditure | $1.79M | $1.90M | $2.84M | $5.27M | $4.68M | $5.61M | $6.35M | $6.22M |
| Free cash flow | $42.7M | $50.3M | $47.0M | $50.2M | $46.0M | $48.6M | $39.6M | $44.2M |
| Share buybacks | $61.5M | $55.1M | $0 | $0 | $0 | $81.7M | $118.6M | $30.0M |
From Progyny Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Progyny Inc
- Headquarters
- New York, New York From SEC filings, Oct 2026
Recent News (5)
-
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period …
-
Progyny COO Melissa Cummings sells $52,612 in shares
Progyny COO Melissa Cummings sells $52,612 in shares
-
Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, announced today that it will present new research evaluatin…
-
Progyny at Wells Fargo healthcare conference: growth runway stays wide
Progyny at Wells Fargo healthcare conference: growth runway stays wide
-
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Chief Financial Officer Mark Livi…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International